Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
dTub
Скачать

M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance

Автор: U.S. Food and Drug Administration

Загружено: 2024-12-06

Просмотров: 1928

Описание:

This webinar provided an update and overview on the final M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms guideline including major changes from the draft guideline and FDA’s current bioequivalence (BE) guidance, delineate FDA’s planning on the implementation of M13A, and addressed questions and provided clarifications based on questions/comments received during public consultation of the draft guideline.

Timestamps

00:45 – Overview of ICH M13 guideline series

25:32 – FDA’s M13A Implementation for Generic Drug Applications: PSG Revisions to Align with M13A

48:36 – FDA’s M13A Implementation for Generic Drug Applications: Focus on PSG Revisions (Additional M13A and Other Revisions)

01:11:00 – Panel Discussion

01:34:24 – Q&A Panel Discussion

01:50:56 – Closing Remarks

Speakers | Panelists:

Lei Zhang, PhD
Deputy Director
Office of Research and Standards (ORS)
Office of Generic drugs (OGD) | CDER

Nilufer Tampal, PhD
Associate Director of Science Quality
Office of Bioequivalence (OB)
OGD | CDER

Myong-Jin (MJ) Kim, PharmD
Director
Division of Therapeutic Performance II (DTPII)
ORS | OGD | CDER

Sarah A. Ibrahim, PhD
Associate Director for Stakeholder and Global Outreach Engagement
OGD | CDER

Robert Lionberger, PhD
Director
ORS | OGD | CDER

Partha Roy, PhD
Director
OB | OGD | CDER

Dave Coppersmith, JD
Regulatory Counsel
Division of Policy Development (DPD)
Office of Generic Drug Policy (OGDP)
OGD | CDER

Qi Zhang, PhD
Immediate Release Drug Products Team Leader
DTPII | ORS | OGD | CDER

Learn more at: https://www.fda.gov/drugs/news-events...

-----------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2024 Playlist -    • 2024 CDER Small Business and Industry Assi...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]
Phone - (301) 796-6707 I (866) 405-5367

M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance

Поделиться в:

Доступные форматы для скачивания:

Скачать видео mp4

  • Информация по загрузке:

Скачать аудио mp3

Похожие видео

Clinical Pharmacology Considerations for Novel Therapeutic Modalities

Clinical Pharmacology Considerations for Novel Therapeutic Modalities

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

Navigating First ICH Generic Drug Draft Guideline M13A Bioequivalence for IR Solid Oral Dosage Forms

Navigating First ICH Generic Drug Draft Guideline M13A Bioequivalence for IR Solid Oral Dosage Forms

FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)

FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Generic Drugs Forum (GDF) 2025 - Day 1

Generic Drugs Forum (GDF) 2025 - Day 1

Advancing Smoking Cessation: FDA and NIH Priorities

Advancing Smoking Cessation: FDA and NIH Priorities

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

FDA's Rare Disease Day 2024—Dedicated to Patients and Providers

FDA's Rare Disease Day 2024—Dedicated to Patients and Providers

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Catching Up on Agency Reforms

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

GCP & Pharmacovigilance Compliance Symposium | D2S06 – Panel Discussion

GCP & Pharmacovigilance Compliance Symposium | D2S06 – Panel Discussion

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Best Practices for Conducting Bioequivalence Studies (16of27) Generic Drugs Forum 2018

Best Practices for Conducting Bioequivalence Studies (16of27) Generic Drugs Forum 2018

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

© 2025 dtub. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]